Phase I and II trials of novel anti-cancer agents : Endpoints, efficacy and existentialism : The Michel Clavel lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998EISENHAUER, E. A.Annals of oncology. 1998, Vol 9, Num 10, pp 1047-1052, issn 0923-7534Article

DNA methyltransferase inhibitors: state of the artGOFFIN, J; EISENHAUER, E.Annals of oncology. 2002, Vol 13, Num 11, pp 1699-1716, issn 0923-7534, 18 p.Article

High-dose chemotherapy: Is it standard management for any common solid tumor?MACNEIL, M; EISENHAUER, E. A.Annals of oncology. 1999, Vol 10, Num 10, pp 1145-1161, issn 0923-7534Article

Current perspectives on camptothecins in cancer treatmentDANCEY, J; EISENHAUER, E. A.British journal of cancer. 1996, Vol 74, Num 3, pp 327-338, issn 0007-0920Article

Validation of novel imaging methodologies for use as cancer clinical trial end-pointsSARGENT, D. J; RUBINSTEIN, L; SCHWARTZ, L et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 290-299, issn 0959-8049, 10 p.Article

Phase II trial of docetaxel in patients with recurrent malignant glioma : a study of the National Cancer Institute of Canada Clinical Trials GroupFORSYTH, P; CAIRNCROSS, G; STEWART, D et al.Investigational new drugs. 1996, Vol 14, Num 2, pp 203-206, issn 0167-6997Article

Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancerTEN BOKKEL HUININK, W. W; EISENHAUER, E; SWENERTON, K et al.Cancer treatment reviews. 1993, Vol 19, pp 79-86, issn 0305-7372, SUPCConference Paper

Phase II study of sulofenur (LY185541) in mesurable metastatic renal cancerWEINERMAN, B; EISENHAUER, E; STEWART, D et al.Annals of oncology. 1992, Vol 3, Num 1, pp 83-84, issn 0923-7534Article

Phase I study of acivicin and cisplatin in non-small-cell lung cancer : a national cancer institute of Canada studyMAROUN, J. A; STEWART, D. J; VERMA, S et al.American journal of clinical oncology. 1990, Vol 13, Num 5, pp 401-404, issn 0277-3732, 4 p.Article

Phase II study of tiazofurin in colorectal cancer: a national cancer institute of Canada studyMAROUN, J. A; EISENHAUER, E; CRIPPS, C et al.Cancer treatment reports. 1987, Vol 71, Num 12, pp 1297-1298, issn 0361-5960Article

Phase II study of acivicin in colorectal carcinoma: a national cancer institute of Canada studyMAROUN, J. A; FIELDS, A. L; PATER, J. L et al.Cancer treatment reports. 1984, Vol 68, Num 9, pp 1121-1123, issn 0361-5960Article

Response Assessment in Solid Tumours (RECIST): Version 1.1 and supporting papersEISENHAUER, E; VERWEIJ, J; THERASSE, P et al.European journal of cancer (1990). 2009, Vol 45, Num 2, issn 0959-8049, 88 p.Serial Issue

Individual patient data analysis to assess modifications to the RECIST criteriaBOGAERTS, Jan; FORD, Robert; SARGENT, Dan et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 248-260, issn 0959-8049, 13 p.Article

Lessons learned from independent central reviewFORD, R; SCHWARTZ, L; VERWEIJ, J et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 268-274, issn 0959-8049, 7 p.Article

Optimising the design of phase II oncology trials : The importance of randomisationRATAIN, Mark J; SARGENT, Daniel J.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 275-280, issn 0959-8049, 6 p.Article

Temozolomide in metastatic breast cancer (MBC) : a phase II trial of the national cancer Institute of Canada - Clinical Trials Group (NCIC-CTG)TRUDEAU, M. E; CRUMP, M; CHARPENTIER, D et al.Annals of oncology. 2006, Vol 17, Num 6, pp 952-956, issn 0923-7534, 5 p.Article

Measuring response in solid tumors : Unidimensional versus bidimensional measurementJAMES, K; EISENHAUER, E; CHRISTIAN, M et al.Journal of the National Cancer Institute. 1999, Vol 91, Num 6, pp 523-528, issn 0027-8874Article

Phase I clinical study of didemnin B : A National Cancer Institute of Canada Clinical Trials Group StudyMAROUN, J. A; STEWART, D; VERMA, S et al.Investigational new drugs. 1998, Vol 16, Num 1, pp 51-56, issn 0167-6997Article

Phase II study of acivicin in non-small cell lung cancer: a national cancer institute of Canada studyMAROUN, J. A; MAKSYMIUK, A; EISENHAUER, E et al.Cancer treatment reports. 1986, Vol 70, Num 11, pp 1327-1328, issn 0361-5960Article

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTGLINDEMANN, K; CHRISTENSEN, R. D; HIRTE, H et al.Annals of oncology. 2012, Vol 23, Num 10, pp 2613-2619, issn 0923-7534, 7 p.Article

Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia : a national cancer institute of canada clinical trials group studyCRUMP, M; LIPTON, J; HEDLEY, D et al.Leukemia. 1999, Vol 13, Num 3, pp 343-347, issn 0887-6924Article

Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancerGELMON, K; EISENHAUER, E; BATIST, G et al.Journal of clinical oncology. 1999, Vol 17, Num 10, pp 3038-3047, issn 0732-183XArticle

Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer : A study of the National Cancer Institute of Canada Trials GroupSHEPHERD, F. A; LATREILLE, J; CRUMP, M et al.Annals of oncology. 1996, Vol 7, Num 3, pp 311-313, issn 0923-7534Article

Phase II study of topotecan in patients with recurrent malignant gliomaMACDONALD, D; CAIRNCROSS, G; STEWART, D et al.Annals of oncology. 1996, Vol 7, Num 2, pp 205-207, issn 0923-7534Article

A phase II study of DuP 937 Teloxantrone in metastatic malignant melanoma: a study of the national cancer institute of Canada clinical trials group (NCICCTG)SHORE, T; EISENHAUER, E; QUIRT, I et al.Annals of oncology. 1993, Vol 4, Num 8, pp 695-696, issn 0923-7534Article